Originally published as JCO Early Release 10.1200/JCO.2005.05.0294 on October 10 2006

This Article Full Text Full Text (PDF) Publisher's Note Erratum (v24,p5790) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harvey, V. Articles by Cold, S. Search for Related Content PubMed PubMed Citation Articles by Harvey, V. Articles by Cold, S.

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

Vernon Harvey, Henning Mouridsen, Vladimir Semiglazov, Erik Jakobsen, Edouard Voznyi, Bridget A. Robinson, Vanina Groult, Michael Murawsky, Soeren Cold

From the Department of Oncology, Auckland Hospital, Auckland; Department of Oncology, Christchurch Hospital, Christchurch, New Zealand; Department of Oncology, Rigshospitalet, Copenhagen; Department of Oncology, Vejle Sygehus, Vejle; Department of Oncology, Odense Universitetssygehus, Odense, Denmark; Department of Oncology, Petrov Research Institute of Oncology, St Petersburg; Department of Oncology, Research Institute of Diagnostics and Surgery, Moscow, Russian Federation; and Sanofi-Aventis, Antony, France; Sanofi-Aventis, Antony, France

Address reprint requests to Vernon Harvey, MD, Department of Oncology, Auckland Hospital, Private Bag 92-024, Auckland, New Zealand; e-mail: vernonh{at}adhb.govt.nz

Purpose: To evaluate whether a relationship exists between docetaxel dose and clinical response in the treatment of patients with advanced breast cancer.

Patients and Methods: Patients whose cancer had progressed after one prior chemotherapy regimen for advanced breast cancer or had recurred during or within 6 months of adjuvant chemotherapy were randomly assigned to docetaxel 60, 75, or 100 mg/m² intravenously every 3 weeks.

Results: Five hundred twenty-seven patients were randomly assigned (intent to treat [ITT]), and 524 were assessable for toxicity. In the population assessable for efficacy (n = 407), logistic regression analysis showed that increasing docetaxel dose was significantly associated with higher response rate (P = .007) and improved time to progression (TTP; P = .014). In the ITT analysis, a significant dose-response relationship was observed for tumor response (P = .026) but not for TTP (P = .067). The incidences of most hematologic and nonhematologic toxicities were related to increasing dose, with grade 3 to 4 neutropenia occurring in 76.4%, 83.7%, and 93.4% and febrile neutropenia occurring in 4.7%, 7.4%, and 14.1% of patients administered the 60, 75, and 100 mg/m² doses, respectively. One death was considered treatment related.

Conclusion: A relationship between increasing dose of docetaxel and increased tumor response was observed across the dose range of 60 to 100 mg/m² every 3 weeks. Toxicities were related to increasing dose. Depending on the therapy goal, any of the doses studied may be appropriate for second-line treatment of advanced breast cancer.

published online ahead of print at www.jco.org on October 10, 2006.

Supported by Sanofi-Aventis, Paris, France.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				L. J. Goldstein, A. O'Neill, J. A. Sparano, E. A. Perez, L. N. Shulman, S. Martino, and N. E. Davidson Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197 J. Clin. Oncol., September 1, 2008; 26(25): 4092 - 4099. [Abstract] [Full Text] [PDF]

				P. Francis, J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, et al. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial J Natl Cancer Inst, January 16, 2008; 100(2): 121 - 133. [Abstract] [Full Text] [PDF]

				K. W. Rahman, S. Ali, A. Aboukameel, S. H. Sarkar, Z. Wang, P. A. Philip, W. A. Sakr, and A. Raz Inactivation of NF-{kappa}B by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells Mol. Cancer Ther., October 1, 2007; 6(10): 2757 - 2765. [Abstract] [Full Text] [PDF]

				M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer Oncologist, March 1, 2007; 12(3): 253 - 270. [Abstract] [Full Text] [PDF]